Tuesday, October 4, 2011
Santaris Pharma A/S, of Horsholm, Denmark, reported data from a Phase IIa trial showing that miravirsen, a microRNA-targeted drug, provided continuous and prolonged antiviral activity well beyond the end of active therapy in hepatitis C virus patients and was well tolerated.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.